Access to innovative medicines in Slovenia

Dostopnost inovativnih zdravil v Sloveniji

  • Andrej Janžič University of Maribor, Faculty of Medicine
Keywords: access to medicines, medicines funding, reimbursement procedure, health technology assessment, joint clinical assessment


Reimbursement is acknowledged to be a critical determinant of patient access to innovative medicines, necessitating a balance between accessibility and financial viability. Approximately 35 new innovative medicines and an additional 20 therapeutic indications are assessed from clinical and economical aspects during the reimbursement procedure every year in Slovenia. At the European Union level, ongoing efforts to unify assessment procedures of clinical domains are underway. These initiatives should improve the reimbursement process and ensure timely access to innovative therapies that will be aligned to the evolving needs of healthcare systems across the European Union. 


Download data is not yet available.

Author Biography

Andrej Janžič, University of Maribor, Faculty of Medicine

Maribor, Slovenia.

How to Cite
Janžič A. (2023). Access to innovative medicines in Slovenia . Acta Medico-Biotechnica, 16(2), 19-25.